Example：10.1021/acsami.1c06204 or Chem. Rev., 2007, 107, 2411-2502
Neurophysiological and clinical effects of the NMDA receptor antagonist lanicemine (BHV-5500) in PTSD: A randomized, double-blind, placebo-controlled trial Depression and Anxiety (IF6.505), Pub Date : 2021-07-12, DOI: 10.1002/da.23194 Nithya Ramakrishnan, Marijn Lijffijt, Charles E. Green, Nicholas L. Balderston, Nicholas Murphy, Christian Grillon, Tabish Iqbal, Brittany Vo-Le, Brittany O'Brien, James W. Murrough, Alan C. Swann, Sanjay J. Mathew
Posttraumatic stress disorder (PTSD) is associated with hyperarousal and stress reactivity, features consistent with behavioral sensitization. In this Phase 1b, parallel-arm, randomized, double-blind, placebo-controlled trial, we tested whether the selective low-trapping N-methyl-D-aspartate receptor (NMDAR) antagonist [Lanicemine (BHV-5500)] blocks expression of behavioral sensitization.